Literature DB >> 6933561

Helper virus is not required for in vitro erythroid transformation of hematopoietic cells by Friend virus.

W D Hankins, S B Krantz.   

Abstract

The Friend polycythemia virus complex (FVP), consisting of the replication-defective spleen focus-forming virus (SFFV) and a helper Friend murine leukemia virus (MuLV-F), produces erythroleukemia within 2-3 weeks in vivo. We have recently reported in vitro transformation of bone marrow cells by FVP, producing clusters of erythroid colonies (erythroid bursts) 4-6 days after infection. In contrast to uninfected bone marrow cells, FVP-treated cells proliferated and differentiated (synthesized hemoglobin) in the absence of added erythropoietin, the physiologic regulator of erythropoiesis. The relative roles of helper murine leukemia virus (MuLV) and SFFV in the in vitro erythroid transformation have now been examined. Pseudotype studies and the finding that cloned MuLV-F (free of SFFV) did not induce burst formation indicated that SFFV was essential for this in vitro effect of FVP. Because SFFV could not be obtained free of helper MuLV, we assessed the requirement of MuLV in the transformation by kinetic analyses of helper-deficient and helper-excess FVP preparations. Whereas helper-excess FVP gave single-hit kinetics both in vivo and in vitro, the helper-deficient FVP followed multiple-hit kinetics when titrated for spleen focus formation in vivo. Addition of MuLV-F to helper-deficient FVP prior to injection resulted in a marked enhancement of spleen focus formation and a conversion from multiple-hit to single-hit kinetics. In contrast, titration of this same preparation for erythroid burst transformation in vitro yielded single-hit kinetics, and the addition of helper MuLV-F had no effect. The time course of burst development was similar with or without added MuLV-F. Unlike burst transformation, SFFV production by these infected cultures followed multiple-hit kinetics. Addition of MuLV-F at the time of infection led to an enhancement of SFFV production and conversion of the titration curve from multiple-hit to single-hit. These data are consistent with the idea that SFFV is competent for erythroid transformation in vitro, but requires helper MuLV for its replication.

Entities:  

Mesh:

Year:  1980        PMID: 6933561      PMCID: PMC350043          DOI: 10.1073/pnas.77.9.5287

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Host-induced changes in infectivity of Friend spleen focus-forming virus.

Authors:  R A Steeves; R J Eckner
Journal:  J Natl Cancer Inst       Date:  1970-03       Impact factor: 13.506

2.  In vitro expression of erythroid differentiation induced by Friend polycythaemia virus.

Authors:  W D Hankins; S B Krantz
Journal:  Nature       Date:  1975-02-27       Impact factor: 49.962

3.  ASSAY FOR FRIEND LEUKEMIA VIRUS: RAPID QUANTITATIVE METHOD BASED ON ENUMERATION OF MACROSCOPIC SPLEEN FOCI IN MICE.

Authors:  A A AXELRAD; R A STEEVES
Journal:  Virology       Date:  1964-11       Impact factor: 3.616

4.  Erythropoietin-independent erythroid colony formation in vitro by hemopoietic cells of mice infected with friend virus.

Authors:  S K Liao; A A Axelrad
Journal:  Int J Cancer       Date:  1975-03-15       Impact factor: 7.396

5.  Isolation of a fibroblast nonproducer cell line containing the Friend strain of the spleen focus-forming virus.

Authors:  D H Troxler; W P Parks; W C Vass; E M Scolnick
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

6.  Isolation and characterization of a lymphatic leukemia virus in the Friend virus complex.

Authors:  R A Steeves; R J Eckner; M Bennett; E A Mirand; P J Trudel
Journal:  J Natl Cancer Inst       Date:  1971-06       Impact factor: 13.506

7.  Malignant transformation and erythroid differentiation by polycythaemia-inducing Friend virus.

Authors:  P Tambourin; F Wendling
Journal:  Nat New Biol       Date:  1971-12-22

8.  Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide.

Authors:  C Friend; W Scher; J G Holland; T Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1971-02       Impact factor: 11.205

9.  Production of altered cell foci in tissue culture by defective Moloney sarcoma virus particles.

Authors:  J W Hartley; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1966-04       Impact factor: 11.205

10.  Friend leukemia: rapid development of erythropoietin-independent hematopoietic precursors.

Authors:  J S Horoszewicz; S S Leong; W A Carter
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

View more
  6 in total

1.  The myeloproliferative sarcoma virus causes transformation or erythroid progenitor cells in vitro.

Authors:  W D Hankins; T A Kost; I B Pragnell
Journal:  Mol Cell Biol       Date:  1982-02       Impact factor: 4.272

2.  Sequence comparisons of the anemia- and polycythemia-inducing strains of Friend spleen focus-forming virus.

Authors:  L Wolff; J Kaminchik; W D Hankins; S K Ruscetti
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

3.  Integration of spleen focus-forming virus proviruses in Friend tumor cells.

Authors:  F Moreau-Gachelin; J Robert-Lezenes; F Wendling; A Tavitian; P Tambourin
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

4.  A tagged helper-free Friend virus causes clonal erythroblast immortality by specific proviral integration in the cellular genome.

Authors:  C Spiro; B Gliniak; D Kabat
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

5.  Roles of helper and defective retroviral genomes in murine erythroleukemia: studies of spleen focus-forming virus in the absence of helper.

Authors:  R K Bestwick; W D Hankins; D Kabat
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

6.  Induction of the early stages of Friend erythroleukemia with helper-free Friend spleen focus-forming virus.

Authors:  S A Berger; N Sanderson; A Bernstein; W D Hankins
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.